Key result
Older age (≥75 vs <65 years) was associated with lower 12-month quadruple GDMT use, while 6-month quadruple therapy reduced HF hospitalization or death.
Why the study?
Elderly patients constitute a growing proportion of patients with HFrEF, yet remain underrepresented in randomized clinical trials, motivating an evaluation of the impact of age on GDMT implementation and tolerability.
Does age impact the implementation, tolerability, and clinical outcomes (first HF hospitalization or all-cause death) of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction?
Cohort (n=3,367)
Yes
Does age impact the implementation, tolerability, and clinical outcomes (first HF hospitalization or all-cause death) of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction?
Although elderly patients with HFrEF receive less intensive GDMT than younger patients, they experience similar tolerability, LVEF improvement, and reduction in mortality or HF hospitalization from quadruple therapy.
Answers are grounded in this paper and cite their sources.
May support intensified GDMT optimization in older HFrEF patients; extends RCT data by revealing real-world age disparities despite comparable tolerability.
BACKGROUND AND AIMS: Elderly patients constitute a growing proportion of patients with heart failure with reduced ejection fraction (HFrEF), yet remain underrepresented in randomized clinical trials. We evaluated the impact of age on the implementation of guideline-directed medical therapy (GDMT) in HFrEF. METHODS: TITRATE-HF is a prospective, multicentre registry (enrolment June 2022-February 2024) including patients with de novo, chronic, and worsening heart failure (HF). For the current analysis, HFrEF patients were categorized by age (<65, 65-74, and ≥75 years). We assessed GDMT implementation, tolerability, and clinical outcomes (composite endpoint: first HF hospitalization or all-cause death). RESULTS: The cohort included 980 patients aged <65 years (29%), 1120 patients aged 65-74 years (33%), and 1267 patients aged ≥75 years (38%). At 12-month follow-up, younger patients more frequently received GDMT, with quadruple therapy prescribed in 68% of those aged <65 years, 61% aged 65-74 years, and 51% aged ≥75 years (P < .001). In de novo HFrEF, age-related differences were observed within weeks after diagnosis, with faster and more extensive GDMT intensification in younger patients. Still, rates of treatment downgrades and the distribution of side effects were largely similar across age groups. Significant left ventricular ejection fraction (LVEF) improvement was observed in all age groups (all P < .001). The use of quadruple therapy at 6 months was associated with a lower risk of the composite endpoint between 6 and 12 months (adjusted hazard ratio 0.65, 95% confidence interval 0.50-0.86, P = .002), with consistent associations across age groups (P for interaction = .46). CONCLUSIONS: Elderly patients with HFrEF received less intensive GDMT. Age-related differences emerged early after diagnosis, with fewer treatment intensifications in elderly patients but largely similar downgrade rates across age groups. These findings highlight the need for improved implementation strategies to optimize guideline-directed therapy and dosing levels in the ageing HFrEF population.
No takes yet. Share an insight, caveat, or question.
Wilde et al. (2026) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=3,367). Age ≥75 years (and quadruple GDMT use at 6 months) vs. Age <65 years and 65-74 years (or non-quadruple therapy) was evaluated on Quadruple GDMT implementation at 12 months; and composite of first HF hospitalization or all-cause death between 6 and 12 months (HR 0.65, 95% CI 0.50-0.86, p=0.002). Older age (≥75 vs <65 years) was associated with lower 12-month quadruple GDMT use, while 6-month quadruple therapy reduced HF hospitalization or death.
Synapse has enriched 10 related papers. Consider them for comparative context: